recombinant flt3 ligand

Phase 3Biologic

EEastern Cooperative Oncology Group

recombinant flt3 ligand is one of 246 biologic programs targeting Neutropenia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

245

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeutropeniaActive, not recruiting

Metastatic MelanomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Metastatic Prostate CancerActive, not recruiting

Breast CancerActive, not recruiting

MelanomaActive, not recruiting

Prostate CancerActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

NeutropeniaPhase 1

Active, not recruiting

Metastatic MelanomaPhase 1

Active, not recruiting

Metastatic Colorectal CancerPhase 1

Active, not recruiting

Metastatic Prostate CancerPhase 2

Active, not recruiting

Breast CancerPhase 1/Phase 2

Active, not recruiting

MelanomaPhase 2

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Acute Myeloid LeukemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

recombinant flt3 ligand

EEastern Cooperative Oncology Group

Phase 3

1 2

MS Contin

Merck & Co.

Preclinical

2 3

Lexiscan

Astellas

Preclinical

1 4

Adenocard

Astellas

Preclinical

1 5

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

2 9

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 10

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Active, not recruiting

Metastatic Solid Tumors

NCT04616248

Clinical

Trials by Indication[1]

Prostate Cancer3 trials

PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003871·60 enrolled

Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00020254

Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00005039·86 enrolled

Melanoma1 trial

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02129075·60 enrolled

Neutropenia1 trial

Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma

Terminated·NNorthwestern University·Phase 1·NCT00005787·3 enrolled

Metastatic Colorectal Cancer1 trial

Flt3L in Treating Patients With Metastatic Colorectal Cancer

Completed·—·Phase 1·NCT00003431

Metastatic Solid Tumors1 trial

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

Active, not recruiting·UUniversity of Southern California·Phase 1·NCT04616248·14 enrolled

4 more indications

Metastatic Prostate Cancer1 trial

Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00045227

Acute Myeloid Leukemia1 trial

flt3L in Treating Patients With Acute Myeloid Leukemia

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00006223

Metastatic Melanoma1 trial

Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00020540

Breast Cancer1 trial

Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer

Completed·NNorthwestern University·Phase 1/2·NCT00006225

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for recombinant flt3 ligand. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — recombinant flt3 ligand compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for recombinant flt3 ligand. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eastern Cooperative Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: EEastern Cooperative Oncology Group

recombinant flt3 ligand

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Prostate Cancer3 trials

Melanoma1 trial

Neutropenia1 trial

Metastatic Colorectal Cancer1 trial

Metastatic Solid Tumors1 trial

Metastatic Prostate Cancer1 trial

Acute Myeloid Leukemia1 trial

Metastatic Melanoma1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News